UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/886,954	06/21/2001	Maureen J. Charron	96700/667	6743

7590 03/25/2005

Craig J. Arnold, Esq.
AMSTER, ROTHSTEIN & EBENSTEIN
90 Park Avenue
New York, NY 10016

EXAMINER	
NICKOL, GARY B	
ART UNIT	**PAPER NUMBER**
1642	

DATE MAILED: 03/25/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/886,954	CHARRON ET AL.	
	Examiner	Art Unit	
	Gary B. Nickol Ph.D.	1642	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *13 December 2004*.

2a)☐ This action is **FINAL**. 2b)☒ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *1,6-11 and 16-20* is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☒ Claim(s) *11 and 16-20* is/are allowed.

6)☒ Claim(s) *1 and 6-10* is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date _____.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____.
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☒ Other: *(Sequence Comparison)*.

Re: Charron *et al.*

Date of priority: June 21, 2001

Response to Amendment

The Amendment filed 12-13-04 in response to the Office Action of 10-05-2004 is acknowledged and has been entered.

Claims 1, 6-11, 16-20 are pending and are currently under consideration.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office Action.

New Rejection:

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

> A person shall be entitled to a patent unless –
>
> (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1, and 6-10 are rejected under 35 U.S.C. 102(e) as being anticipated by WO 01/90304 A2 (Human Genome Sciences, Inc, May 2000).

WO 01/90304 A2 teaches an isolated clone (HEGAC86, see page 514, SEQ ID NO:2091) that encodes a polypeptide having 61% identity to the claimed GLUTx protein (see attached sequence listing comparison).

The reference further teaches diagnostic assays and methods for determining whether a subject has a defect in cell proliferation comprising assaying a diagnostic sample of the subject for any of the disclosed genes (pages 1832-1841) including wherein the diagnostic sample is assayed using labeled antibodies or labeled nucleic acid probes and wherein the detection of the inventive genes or polypeptides is elevated above normal (see para 0391, page 1840). The reference further teaches that the polypeptides and polynucleotides disclosed can be used to detect certain hyperproliferative disorders including cancers of the breast and endomentrium (pages 1878-1879).

Hence, the claimed method is anticipated because the labeled nucleic acid probes and or labeled antibodies of the prior art would *inherently* cross-react with a GLUTx protein that has the amino acid of SEQ ID NO:1. The steps of the claimed methods are identical to the prior art method and the product of the prior art is substantially identical to the GLUTx protein. Where the claimed and prior art products are identical or substantially identical in structure or composition, or are produced by identical or substantially identical processes, a prima facie case of either anticipation or obviousness has been established. In re Best, 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA 1977).

All other rejections and or objections are withdrawn in view of applicant's amendments and arguments there to.

Claims 11, and 16-20 appear allowable.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gary B. Nickol Ph.D. whose telephone number is 571-272-0835. The examiner can normally be reached on M-Th, 8:30-5:30; alternate Fri., 8:30-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Gary B. Nickol Ph.D.
Primary Examiner
Art Unit 1642

GBN

GARY NICKOL
PRIMARY EXAMINER

```
Qy        121 WMLLGGRLLTGLACGVASLVAPVYISEIAYPAVRGLLGSCVQLMVVVGILLAYLAGWVLE 180
                                 ||||||||||||||||||||||||||||||||||||||
Db         74 ----------------------VYISEIAYPAVRGLLGSCVQLMVVVGILLAYLAGWVLE 111

Qy        181 WRWLAVLGCVPPSLMLLLMCFMPETPRFLLTQHRRQEAMAALRFLWGSEQGWEDPPIGAE 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        112 WRWLAVLGCVPPSLMLLLMCFMPETPRFLLTQHRRQEAMAALRFLWGSEQGWEDPPIGAE 171

Qy        241 QSFHLALLRQPGIYKPFIIGVSLMAFQQLSGVNAVMFYAETIFEEAKFKDSSLASVVVGV 300
                                  ||||||||||||||||||||||||||||||
Db        172 --------------------------QQLSGVNAVMFYAETIFEEAKFKDSSLASVVVGV 205

Qy        301 IQVLFTAVAALIMDRAGRRLLLVLSGVVMVFSTSAFGAYFKLTQGGPGNSSHVAISAPVS 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        206 IQVLFTAVAALIMDRAGRRLLLVLSGVVMVFSTSAFGAYFKLTQGGPGNSSHVAISAPVS 265

Qy        361 AQPVDASVGLAWLAVGSMCLFIAGFAVGWGPIPWLLMSEIFPLHVKGVATGICVLTNWLM 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        266 AQPVDASVGLAWLAVGSMCLFIAGFAVGWGPIPWLLMSEIFPLHVKGVATGICVLTNWLM 325

Qy        421 AFLVTKEFSSLMEVLRPYGAFWLASAFCIFSVLFTLFCVPETKGKTLEQITAHFEGR 477
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        326 AFLVTKEFSSLMEVLRPYGAFWLASAFCIFSVLFTLFCVPETKGKTLEQITAHFEGR 382
```

RESULT 9
ADL33342
ID ADL33342 standard; protein; 353 AA.
XX
AC ADL33342;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human transporter and ion channel (TRICH) protein #46.
XX
KW anti-HIV; antiallergic; antiinflammatory; antianemic; antiparkinsonian;
KW nootropic; anticonvulsant; antiarteriosclerotic; antiasthmatic;
KW immunosuppressive; antithyroid; cytostatic; hepatotropic; dermatological;
KW antidiabetic; aephrotropic; antigout; thyromimetic; neuroprotective;
KW osteopathic; antiarthritic; antiparasitic; antihelmintic; antipsoriatic;
KW uropathic; ophthalmological; antirheumatic; hemostatic; antibacterial;
KW virucide; protozoacide; fungicide; gene therapy.
XX
OS Homo sapiens.
XX
PN WO2003083085-A2.
XX
PD 09-OCT-2003.
XX
PF 27-MAR-2003; 2003WO-US009797.
XX
PR 28-MAR-2002; 2002US-0368840P.
PR 26-APR-2002; 2002US-0375637P.
XX
PA (INCY-) INCYTE CORP.
XX
PI Marquis JP, Lee SY, Emerling BM, Hafalia AJA, Khare R, Kable AE;
PI Richardson TW, Swarnakar A, Chawla NK, Becha SD, Mason PM;
PI Elliott VS, Ramkumar J, Griffin JA, Tran UK, Ison CH, Lindquist EA;
PI Jiang X, Jackson AA, Wilson AD, Jin P, Chang H;
XX
DR WPI; 2003-833535/77.
DR N-PSDB; ADL33401.
XX
PT New human transporters and ion channels (TRICH) and polynucleotides,
PT useful for diagnosing, treating or preventing autoimmune or inflammatory
PT disorders (e.g. AIDS, allergy or anemia), multiple sclerosis, cancer or
PT hepatitis.
XX
PS Claim 1; SEQ ID NO 46; 405pp; English.
XX
CC The invention relates to an isolated polypeptide (I), which is a human
CC intracellular signaling molecule, which is a human intracellular
CC signaling molecule,a naturally occurring amino acid sequence at least 90%
CC -96% identical to it or a biologically active fragment or an immunogenic
CC fragment of the polypeptide. . The human TRICH, polynucleotides, agonists
CC and antagonists are useful for diagnosing, treating or preventing
CC disorders associated with aberrant expression of TRICH, particularly cell
CC proliferative disorders (e.g. arteriosclerosis, atherosclerosis,
CC cirrhosis, hepatitis, paroxysmal nocturnal hemoglobinuria, polycythemia
CC vera, psoriasis, primary thromobocytopenia or cancer), developmental
CC disorders (e.g. renal tubular acidosis, anemia or mental retardation),
CC neurological disorders (e.g. Alzheimers disease, Parkinson's disease or
CC epilepsy), autoimmune/inflammatory disorders (e.g. AIDS, allergies,
CC asthma, autoimmune thyroiditis, contact dermatitis, Crohn's disease,
CC diabetes mellitus, glomerulonephritis, Goodpasture's syndrome, gout,
CC Graves' disease, Hashimoto's thyroiditis, irritable bowel syndrome,
CC multiple sclerosis, osteoarthritis, osteoporosis, pancreatitis, Reiter's
CC syndrome, rheumatoid arthritis, Sjogren's syndrome, uveitis), or viral,
CC bacterial, fungal, parasitic, protozoan or helminthic infections. The
CC polynucleotides encoding TRICH are useful for creating transgenic animals
CC to model human disease. This sequence corresponds to one of the proteins
CC of the invention.
XX
SQ Sequence 353 AA;

Query Match 67.7%; Score 1664; DB 7; Length 353;
Best Local Similarity 100.0%; Pred. No. 8e-151;
Matches 326; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTPEDPEETQPLLGPPGGSAPRGRRVFLAAFAAALGPLSFGFALGYSSPAIPSLQRAAPP 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTPEDPEETQPLLGPPGGSAPRGRRVFLAAFAAALGPLSFGFALGYSSPAIPSLQRAAPP 60

Qy         61 APRLDDAAASWFGAVVTLGAAAGGVLGGWLVDRAGRKLSLLLCSVPFVAGFAVITAAQDV 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 APRLDDAAASWFGAVVTLGAAAGGVLGGWLVDRAGRKLSLLLCSVPFVAGFAVITAAQDV 120

Qy        121 WMLLGGRLLTGLACGVASLVAPVYISEIAYPAVRGLLGSCVQLMVVVGILLAYLAGWVLE 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 WMLLGGRLLTGLACGVASLVAPVYISEIAYPAVRGLLGSCVQLMVVVGILLAYLAGWVLE 180

Qy        181 WRWLAVLGCVPPSLMLLLMCFMPETPRFLLTQHRRQEAMAALRFLWGSEQGWEDPPIGAE 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 WRWLAVLGCVPPSLMLLLMCFMPETPRFLLTQHRRQEAMAALRFLWGSEQGWEDPPIGAE 240

Qy        241 QSFHLALLRQPGIYKPFIIGVSLMAFQQLSGVNAVMFYAETIFEEAKFKDSSLASVVVGV 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 QSFHLALLRQPGIYKPFIIGVSLMAFQQLSGVNAVMFYAETIFEEAKFKDSSLASVVVGV 300

Qy        301 IQVLFTAVAALIMDRAGRRLLLVLSG 326
              |||||||||||||||||||||||||
Db        301 IQVLFTAVAALIMDRAGRRLLLVLSG 326
```

RESULT 10
ABB89717
ID ABB89717 standard; protein; 326 AA.
XX
AC ABB89717;
XX
DT 24-MAY-2002 (first entry)
XX
DE Human polypeptide SEQ ID NO 2093.
XX
KW Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
KW antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer;
KW vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic;
KW cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
KW neurological disease; infection; human; secreted protein.
XX
OS Homo sapiens.
XX
PN WO200190304-A2.
XX
PD 29-NOV-2001.

XX
PF 18-MAY-2001; 2001WO-US016450.
XX
PR 19-MAY-2000; 2000US-0205515P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Birse CE, Rosen CA;
XX
DR WPI; 2002-122018/16.
DR N-PSDB; ABL90126.
XX
PT Novel 1405 isolated polypeptides, useful for diagnosis, treatment and
PT prevention of neural, immune system, muscular, reproductive,
PT gastrointestinal, pulmonary, cardiovascular, renal and proliferative
PT disorders.
XX
PS Claim 11; SEQ ID NO 2093; 2081pp + Sequence Listing; English.
XX
CC The invention relates to novel genes (ABL89449-ABL90853) and proteins
CC (ABB89040-ABB90444) useful for preventing, treating or ameliorating
CC medical conditions e.g. by protein or gene therapy. The genes are
CC isolated from a range of human tissues disclosed in the specification.
CC The nucleic acids, proteins, antibodies and (ant)agonists are useful in
CC the diagnosis, treatment and prevention of: (a) cancer, e.g. breast and
CC ovarian cancer and other cancers of the adrenal gland, bone, bone marrow,
CC breast, gastrointestinal tract, liver, lung, or urogenital; (b) immune
CC disorders e.g. Addison's disease, allergies, autoimmune haemolytic
CC anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,
CC multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c)
CC cardiovascular disorders such as myocardial ischaemias; (d) wound healing
CC ; (e) neurological diseases e.g. cerebral anoxia and epilepsy; and (f)
CC infectious diseases such as viral, bacterial, fungal and parasitic
CC infections. Note: The sequence data for this patent did not form part of
CC the printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 326 AA;

Query Match 60.7%; Score 1491; DB 5; Length 326;
Best Local Similarity 96.3%; Pred. No. 2.9e-134;
Matches 289; Conservative 1; Mismatches 10; Indels 0; Gaps 0;

```
Qy      164 MVVVGILLAYLAGWVLEWRWLAVLGCVPPSLMLLLMCFMPETPRFLLTQHRRQEAMAALR 223
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        1 MVVVGILLAYLAGWVLEWRWLAVLGCVPPSLMLLLMCFMPETPRFLLTQHRRQEAMAALR 60

Qy      224 FLWGSEQGWEDPPIGAEQSFHLALLRQPGIYKPFIIGVSLMAFQQLSGVNAVMFYAETIF 283
            |||||||||||||| |||||||| ||||||||||||||||||||||||||||||||||||
Db       61 FLWGSEQGWEDPPIGXEQSFHLALLRXPGIYKPFIIGVSLMAFQQLSGVNAVMFYAETIF 120

Qy      284 EEAKFKDSSLASVVVGVIQVLFTAVAALIMDRAGRRLLLVLSGVVMVFSTSAFGAYFKLT 343
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      121 EEAKFKDSSLASVVVGVIQVLFTAVAALIMDRAGRRLLLVLSGVVMVFSTSAFGAYFKLT 180

Qy      344 QGGPGNSSHVAISAPVSAQPVDASVGLAWLAVGSMCLFIAGFAVGWGPIPWLLMSEIFPL 403
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      181 QGGPGNSSHVAISAPVSAQPVDASVGLAWLAVGSMCLFIAGFAVGWGPIPWLLMSEIFPL 240

Qy      404 HVKGVATGICVLTNWLMAFLVTKEFSSLMEVLRPYGAFWLASAFCIFSVLFTLFCVPETK 463
            |||||||| ||| |||| || |||||||||||||||||||||||||||||| |  : |
Db      241 HVKGVATGXCVLXNWLMXFLXTKEFSSLMEVLRPYGAFWLASAFCIFSVLFTLVCALKLK 300
```

RESULT 11
AAE06579
ID AAE06579 standard; protein; 262 AA.
XX
AC AAE06579;
XX
DT 25-SEP-2001 (first entry)
XX
DE Human protein having hydrophobic domain, HP10784.
XX
KW Human; hydrophobic domain; gene therapy; nutritional supplement;
KW cell proliferation; immunomodulatory; autoimmune disorder; antimicrobial;
KW multiple sclerosis; rheumatoid arthritis; insulin-dependent diabetes;
KW haematopoiesis; tissue growth activity; Parkinson's disease; cytostatic;
KW Huntington's disease; Alzheimer's disease; chemotactic; chemokinetic;
KW haemostatic; thrombolytic; tumour growth inhibitor; anabolic;
KW contraceptive; antiinfertility; antiinflammatory.
XX
OS Homo sapiens.
XX
PN WO200149728-A2.
XX
PD 12-JUL-2001.
XX
PF 28-DEC-2000; 2000WO-JP009359.
XX
PR 06-JAN-2000; 2000JP-00000585.
PR 06-JAN-2000; 2000JP-00000588.
PR 11-JAN-2000; 2000JP-00002299.
PR 03-FEB-2000; 2000JP-00026862.
PR 03-MAR-2000; 2000JP-00058367.
XX
PA (PROT-) PROTEGENE INC.
PA (SAGA) SAGAMI CHEM RES CENT.
XX
PI Kato S, Kimura T;
XX
DR WPI; 2001-418355/44.
DR N-PSDB; AAD12574.
XX
PT Human proteins with hydrophobic domains and the nucleic acids encoding
PT them, useful for preventing diagnosing and treating e.g. cancer,
PT Alzheimer's and inflammation.
XX
PS Claim 1; Page 75; 563pp; English.
XX
CC The present sequence is human protein with hydrophobic domain, HP10784.
CC The polynucleotide and polypeptide of the invention may be used in the
CC prevention, diagnosis and treatment of diseases associated with
CC inappropriate polypeptide expression. The polynucleotides may be used to
CC produce the polypeptide, by inserting the nucleic acids into a host cell
CC and culturing the cell to express the protein. The polynucleotides and
CC its complementary sequences may also be used as DNA probes in diagnostic
CC assays and also used in gene therapy. The polypeptides may also be used
CC as antigens in the production of antibodies and in assays to identify
CC modulators of polypeptide expression and activity. The polypeptides and
CC nucleic acids may be used as nutritional supplements, to modulate
CC cytokine and cell proliferation activity, to modulate immune stimulation
CC or suppression (e.g. for the treatment of microbial infections and
CC autoimmune disorders such as multiple sclerosis, rheumatoid arthritis and
CC insulin-dependent diabetes), to modulate haematopoiesis, to modulate
CC tissue growth activity (e.g. for the treatment of Parkinson's disease,
CC Huntington's disease and Alzheimer's disease), to modulate activin and
CC inhibin activity (e.g. for controlling fertility), to modulate
CC chemotactic and chemokinetic activity, to modulate haemostatic and
CC thrombolytic activity, to modulate receptor ligand activity, to modulate
CC inflammation and to inhibit tumour growth
XX
SQ Sequence 262 AA;

Query Match 46.2%; Score 1135; DB 4; Length 262;
Best Local Similarity 91.4%; Pred. No. 3.3e-100;
Matches 223; Conservative 2; Mismatches 7; Indels 12; Gaps 1;

```
Qy        1 MTPEDPEETQPLLGPPGGSAPRGRRVFLAAFAAALGPLSFGFALGYSSPAIPSLQRAAPP 60
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        1 MTPEDPEETQPLLGPPGGSAPRGRRVFLAAFAAALGPLSFGFALGYSSPAIPSLQRAAPP 60

Qy       61 APRLDDAAASWFGAVVTLGAAAGGVLGGWLVDRAGRKLSLLLCSVPFVAGFAVITAAQDV 120
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       61 APRLDDAAASWFGAVVTLGAAAGGVLGGWLVDRAGRKLSLLLCSVPFVAGFAVITAAQDV 120
```